[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]

BACKGROUND: Peginterferon beta-1a, injected every two weeks, is the first approved pegylated interferon beta-1a for the treatment of relapsing remitting multiple sclerosis (RRMS). The objective of this analysis was to estimate the economic impact due to the introduction of peginterferon beta-1a in I...

Full description

Bibliographic Details
Main Authors: Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Giulia Vestri, Luigi Giuliani, Diego Centonze, Pier Luigi Canonico
Format: Article
Language:English
Published: SEEd Medical Publishers 2016-07-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
budget impact analysis
peginterferon beta-1a
multiple sclerosis
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1231

Similar Items

Similar Items